![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
Lead Product(s): Fondaparinux Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arixtra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: $757.2 million Upfront Cash: $310.4 million
Deal Type: Acquisition September 08, 2020